Najat C Daw1, Nadia N Laack2, Elizabeth J McIlvaine3, Mark Krailo3, Richard B Womer4, Linda Granowetter5, Holcombe E Grier6, Neyssa M Marina7, Mark L Bernstein8, Mark C Gebhardt9, Karen J Marcus10, Shailesh M Advani11, John H Healey12, George D Letson13, Richard G Gorlick14, R Lor Randall15. 1. Division of Pediatrics, UT MD Anderson Cancer Center, Unit 87, 1515 Holcombe Boulevard, Houston, TX, USA. ndaw@mdanderson.org. 2. Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA. 3. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 4. Department of Pediatrics, University of Pennsylvania Perelman School of Medicine and Children's Hospital of Philadelphia, Philadelphia, PA, USA. 5. Department of Pediatrics, New York University (NYU) School of Medicine and NYU Langone Medical Center, New York, NY, USA. 6. Department of Pediatrics, Children's Hospital Boston/Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. 7. Department of Pediatrics, Stanford University School of Medicine and Lucile Packard Children's Hospital, Palo Alto, CA, USA. 8. Division of Pediatric Hematology/Oncology, IWK Health Center, Halifax, Nova Scotia, Canada. 9. Department of Orthopedic Surgery, Children's Hospital Boston/Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. 10. Department of Radiation Oncology, Children's Hospital Boston/Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. 11. Division of Pediatrics, UT MD Anderson Cancer Center, Unit 87, 1515 Holcombe Boulevard, Houston, TX, USA. 12. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 13. Department of Surgery, All Children's Hospital, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. 14. Section of Pediatric Hematology/Oncology, Montefiore Medical Center-Moses Campus, Bronx, NY, USA. 15. Department of Orthopaedics, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA.
Abstract
BACKGROUND: The choice of a local control (LC) modality for Ewing sarcoma (EWS) of the femur is controversial. This study aimed to determine the effect of LC modality on tumor LC and patient outcomes. METHODS: The study reviewed the treatment and outcomes for 115 patients who had EWS of the femur treated with similar chemotherapy in three cooperative group trials. Patient outcomes were analyzed according to the LC modality using the log-rank test and the cumulative incidence of local or distant failure using competing risks regression. RESULTS: The median age of the patients was 13 years. The most common tumor location was the proximal femur followed by the mid femur. For 55 patients with available data, the tumor was larger than 8 cm in 29 patients and 8 cm or smaller in 26 patients. For 84 patients (73 %), surgery only was performed, whereas 17 patients (15 %) had surgery plus radiation, and 14 patients (12 %) had radiation only. The 5-year event-free survival (EFS) rate was 65 % (95 % confidence interval [CI], 55-73 %), and the 5-year overall survival (OS) rate was 70 % (95 % CI, 61-78 %). Patient outcomes did not differ significantly according to tumor location within the femur (proximal, mid or distal) or tumor size (<8 vs ≥8 cm). The findings showed no statistically significant differences in EFS, OS, cumulative incidence of local failure, or cumulative incidence of distant failure according to LC modality (surgery, surgery plus radiation, or radiation). CONCLUSIONS: The LC modality did not significantly affect disease outcome for EWS of the femur. Further study of treatment complications and functional outcome may help to define the optimal LC modality.
BACKGROUND: The choice of a local control (LC) modality for Ewing sarcoma (EWS) of the femur is controversial. This study aimed to determine the effect of LC modality on tumorLC and patient outcomes. METHODS: The study reviewed the treatment and outcomes for 115 patients who had EWS of the femur treated with similar chemotherapy in three cooperative group trials. Patient outcomes were analyzed according to the LC modality using the log-rank test and the cumulative incidence of local or distant failure using competing risks regression. RESULTS: The median age of the patients was 13 years. The most common tumor location was the proximal femur followed by the mid femur. For 55 patients with available data, the tumor was larger than 8 cm in 29 patients and 8 cm or smaller in 26 patients. For 84 patients (73 %), surgery only was performed, whereas 17 patients (15 %) had surgery plus radiation, and 14 patients (12 %) had radiation only. The 5-year event-free survival (EFS) rate was 65 % (95 % confidence interval [CI], 55-73 %), and the 5-year overall survival (OS) rate was 70 % (95 % CI, 61-78 %). Patient outcomes did not differ significantly according to tumor location within the femur (proximal, mid or distal) or tumor size (<8 vs ≥8 cm). The findings showed no statistically significant differences in EFS, OS, cumulative incidence of local failure, or cumulative incidence of distant failure according to LC modality (surgery, surgery plus radiation, or radiation). CONCLUSIONS: The LC modality did not significantly affect disease outcome for EWS of the femur. Further study of treatment complications and functional outcome may help to define the optimal LC modality.
Authors: Bradley J Stish; Safia K Ahmed; Peter S Rose; Carola A Arndt; Nadia N Laack Journal: Pediatr Blood Cancer Date: 2015-08-14 Impact factor: 3.167
Authors: T Ozaki; A Hillmann; C Hoffmann; C Rübe; B Dockhorn-Dworniczak; S Blasius; J Dunst; J Treuner; H Jürgens; W Winkelmann Journal: Acta Orthop Scand Date: 1997-02
Authors: G Bacci; S Ferrari; F Bertoni; S Rimondini; A Longhi; P Bacchini; C Forni; M Manfrini; D Donati; P Picci Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: J F Kuttesch; L H Wexler; R B Marcus; D Fairclough; L Weaver-McClure; M White; L Mao; T F Delaney; C B Pratt; M E Horowitz; L E Kun Journal: J Clin Oncol Date: 1996-10 Impact factor: 44.544
Authors: Holcombe E Grier; Mark D Krailo; Nancy J Tarbell; Michael P Link; Christopher J H Fryer; Douglas J Pritchard; Mark C Gebhardt; Paul S Dickman; Elizabeth J Perlman; Paul A Meyers; Sarah S Donaldson; Sheila Moore; Aaron R Rausen; Teresa J Vietti; James S Miser Journal: N Engl J Med Date: 2003-02-20 Impact factor: 91.245
Authors: Y Arai; L E Kun; M T Brooks; D L Fairclough; J Fontanesi; W H Meyer; F A Hayes; E Thompson; B N Rao Journal: Int J Radiat Oncol Biol Phys Date: 1991-11 Impact factor: 7.038
Authors: Gregory C Stachelek; John A Ligon; Jennifer Vogel; Adam S Levin; Nicolas J Llosa; Brian H Ladle; Christian F Meyer; Stephanie A Terezakis; Carol D Morris; Matthew M Ladra; Christine A Pratilas Journal: Sarcoma Date: 2021-04-17